Leadership

Working in healthcare isn’t just a job. It’s a calling—to develop solutions that transform patients’ lives and help healthcare professionals provide the best care. Meet the team that inspires our employees to fulfill that purpose and ensures high performance for our shareholders.

Executive Committee

Board of Directors

Michael “Mike” Mahoney is Chief Executive Officer of Boston Scientific Corporation and Chairman of the company’s Board of Directors. Boston Scientific is a global medical technology leader with more than $8 billion in annual revenue and commercial representation in more than 100 countries. Under Mahoney’s leadership, Boston Scientific is delivering on its mission to transform lives through innovative medical solutions that improve the health of patients around the world. The company’s team of more than 25,000 global employees reaches 22 million patients each year, providing a range of technologies and solutions that span cardiovascular and peripheral interventions, cardiac rhythm management, endoscopy, neuromodulation and urology and pelvic health. Mahoney joined Boston Scientific in 2011 as President, and became President, Chief Executive Officer and a member of the Board of Directors in 2012. He was elected Chairman in 2016.

Since joining Boston Scientific, Mahoney has focused the company on addressing the needs of the evolving healthcare landscape by driving improvements to patient outcomes and increasing healthcare economic efficiency and access. Under his leadership, Boston Scientific has brought many transformational medical devices to market while creating significant value to its shareholders.

Mahoney’s career spans more than 25 years of success building market-leading medical device, capital equipment and healthcare IT businesses. Prior to Boston Scientific, he served as Worldwide Chairman of the Medical Devices and Diagnostics (MD&D) division of Johnson & Johnson, where he oversaw seven franchises and 50,000 employees. Previously, he served as Worldwide Group Chairman of Johnson & Johnson’s DePuy orthopedics and neuro-sciences business, where he drove growth through product innovation, acquisitions and market expansion into China and India.

Prior to joining DePuy, Mahoney was President and Chief Executive Officer of Global Healthcare Exchange (GHX), a joint venture between Johnson & Johnson, General Electric and three other leaders in the medical device, hospital and technology industries. For the first 12 years of his career, Mahoney advanced through a series of leadership roles at General Electric Medical Systems, including General Manager of the company’s Healthcare Information Technology business.

Mahoney serves on the Board of Directors of Baxter International and the American Heart Association leadership council. He earned a B.B.A. in Finance from the University of Iowa and his M.B.A. from Wake Forest University. He is married and has three children.

Kevin Ballinger is Executive Vice President and Global President, Interventional Cardiology for Boston Scientific and a member of its Executive Committee. In his current role, Ballinger is responsible for developing and bringing to market innovative solutions that diagnose and treat coronary artery disease and structural heart disorders. 

Ballinger has more than 20 years of interventional cardiology experience. Prior his current role, he served as President of the Boston Scientific Interventional Cardiology business unit and held a variety of engineering and general management positions, including overseeing the development of the company’s first drug-eluting stents. 

Ballinger earned a B.S. in Mechanical Engineering from Michigan Technological University and an M.B.A. from the University of Minnesota.

Supratim Bose is Executive Vice President and President, Asia-Pac, Middle East and Africa (AMEA)for Boston Scientific and a member of its Executive Committee. In this role, Supratim oversees the Company’s business and growth opportunities across Asia-Pacific, the world’s fastest growing region, plus the Middle East and Africa.

Before joining Boston Scientific in January 2012, Supratim was Founder and Chief Executive Officer of Singapore-based Bose Consulting Group, which specialized in strategic management consulting services for the healthcare industry. Previously, he worked for nearly 30 years at Johnson & Johnson, where he concluded his tenure as Company Group Chairman of its Medical Devices and Diagnostics (MD&D) business. In this role, he managed Johnson & Johnson’s MD&D companies throughout Asia-Pacific, including Japan, having pioneered its entry in all emerging markets in Asia, including China, India, and Vietnam. During his tenure, he also created the company’s research and development capability in the region and led the development and growth of local talent. Under Supratim’s leadership, the organization partnered closely with key external stakeholders to shape the healthcare environment, and was recognized by external agencies as one of the top companies to work for in Asia-Pacific.

Daniel Brennan is Executive Vice President and Chief Financial Officer for Boston Scientific Corporation and a member of its Executive Committee. In this role, he is responsible for several Company functions, including Global Controllership, Corporate Finance, Treasury, Corporate Tax, Corporate Analysis and Control, and Corporate New Business Development.

Previously, he served as Senior Vice President and Corporate Controller. In this role, Brennan was responsible for the Global Controllership organization, including the Company’s accounting and financial planning processes.

Arthur Butcher is Senior Vice President and President, Endoscopy Division for Boston Scientific. In this role, he is responsible for developing and bringing to market less invasive devices for treating gastrointestinal and pulmonary conditions.

Prior to his current role, Butcher was Vice President & General Manager, Japan Endoscopy Business. Since joining the Company in 1997, he has held a variety of marketing and strategic planning management positions within the Endoscopy and Urology and Pelvic Health divisions.

Butcher holds a B.A. in International Relations from the University of Pennsylvania and an M.B.A. from Columbia University.

Wendy Carruthers is Senior Vice President of Human Resources for Boston Scientific Corporation and a member of its Executive Committee. In this role, she provides strategic leadership to the global HR function, including HR operations, total rewards, talent management, diversity and inclusion, and community relations.

Prior to her current role, Carruthers served as Vice President of Global Talent Management for Boston Scientific, responsible for all aspects of global talent management including the design, development and implementation of global processes and systems to enable managers to identify, attract and develop people.

Carruthers has been with Boston Scientific since 2004 and was previously Vice President of Human Resources for the company’s Europe, Middle East and Africa (EMEA) region, based in Paris.

Professor Ian Meredith is Executive Vice President and Global Chief Medical Officer for Boston Scientific and a member of the Executive Committee. In this role, he is responsible for leading clinical and medical affairs across Boston Scientific and providing global leadership of the company’s clinical trial strategy.

Prior to joining Boston Scientific in 2017, Professor Meredith served as Professor and Director of MonashHeart, the Cardiology service within Monash Health in Melbourne, Australia and one of the largest cardiac care services in Australia. He was also Professor of Medicine and Cardiology at Monash University in Melbourne and Executive Director of the Monash Cardiovascular Research Centre at Monash University.

With more than 25 years of experience as a clinical and interventional cardiologist, Professor Meredith has performed more than 12,000 cardiac and coronary procedures, published more than 350 peer-reviewed manuscripts and book chapters and championed many new treatment paradigms into daily clinical practice. He has been the chief or principal investigator on more than 50 major international multi-center trials and was the global principal investigator for the Boston Scientific Lotus™ Valve REPRISE research program.

Joe Fitzgerald is Executive Vice President and President, Rhythm Management for Boston Scientific and a member of its Executive Committee.

Prior to his current role, Fitzgerald was President of Boston Scientific's Endovascular Unit, which included the Company's Peripheral Interventions, Electrophysiology, Neurovascular and IVUS businesses. Previously, he held a number of senior leadership positions at Boston Scientific, including President of our Electrophysiology business and Vice President of Global Marketing and U.S. Sales for the Company's Neurovascular business.

Edward Mackey is Executive Vice President, Global Operations for Boston Scientific and a member of its Executive Committee. In this role, he is responsible for Global Manufacturing and Supply Chain, Quality and Regulatory Affairs, Information Technology, Global Business Services, Global Business Excellence, Corporate Research and Development and Corporate Marketing and Market Access. Mackey is the chair of the Boston Scientific Technical Executive Committee and is responsible for overseeing emerging areas such as digital health and the cancer solutions team. 

Mackey is a seasoned executive with a track record of delivering strong results, leading large teams and developing innovative strategies. Prior to joining Boston Scientific in 2015, Mackey was Worldwide President of DePuy Synthes Power Tools, a division of Johnson & Johnson, after having served as Vice President of Integration for Johnson & Johnson’s acquisition of Synthes. 

Earlier in his career, Mackey held management positions in Operations, Quality and Product Development at Raytheon’s Missile Systems division. In 1995, he moved to Johnson & Johnson Orthopaedics as a plant manager and progressed through a series of manufacturing and supply chain leadership roles, becoming Worldwide Vice President of Supply Chain and Manufacturing for DePuy in 2007. 

Mackey holds a B.S. in Mechanical Engineering from Worcester Polytechnic Institute and an M.B.A. from the University of Massachusetts.

Jeff Mirviss is Senior Vice President and President, Peripheral Interventions for Boston Scientific and a member of its Executive Committee. In that capacity he is responsible for developing and bringing to market innovative solutions for treating patients with high blood pressure, vascular system blockages and cancer.

Mirviss has more than 23 years of experience in medical device and pharmaceutical general management, marketing and sales. He has held positions of increasing responsibility since 1997 at Boston Scientific.

In addition to his roles at Boston Scientific, Mirviss has worked for companies ranging in size from a pre-revenue venture-backed medical device startup to Dow 30 companies.

A resident of Plymouth, Minnesota, Mirviss holds a Bachelor’s degree from the University of Minnesota and an MBA from the University of St. Thomas. 

Maulik Nanavaty is Senior Vice President and President, Neuromodulation Division for Boston Scientific and a member of its Executive Committee. In this role, he is responsible for the innovation leader in less-invasive microelectronic implantable technologies used to treat chronic neuropathic pain.

Prior to his current role, Nanavaty was President, Representative Director of Boston Scientific Japan. Previously, he was Vice President and General Manager of the Company's Interventional Cardiology business in Japan. During his tenure, Nanavaty managed the successful expansion of Cardiology business in that country. He joined Boston Scientific in 2005 as Vice President for Corporate Strategy for Japan, where he led business transformation and increased operational efficiency.

Michael Phalen is Executive Vice President and President, Medical Surgery (MedSurg) for Boston Scientific and a member of its Executive Committee. In this role, he plans and executes Boston Scientific’s growth strategies for the Company’s Endoscopy, Urology/Women’s Health and Neuromodulation businesses. Phalen also oversees Boston Scientific operations in Canada and Latin America.

Prior to assuming his current position in January 2012, Phalen was President of Boston Scientific International. He was responsible for planning and executing Boston Scientific’s international growth strategy.

Dave Pierce is Senior Vice President and President, Urology and Pelvic Health for Boston Scientific and a member of its Executive Committee. In this role, he develops and executes strategies to bring to market industry-leading solutions for treating patients with urological, urogynecological, and gynecological diseases.

Prior to his current role, Pierce was Senior Vice President and President, Endoscopy Division, leading the Endoscopy business with a focus on strategic portfolio expansion and global commercial execution. He joined the Company in 1991 as a Territory Manager before assuming various management-level positions of increasing responsibility.

Before joining Boston Scientific, Pierce worked as a Senior Sales Representative for Airborne Express and served as a Captain in the United States Army.

Pierce earned a B.S. in Business Administration from Norwich University and an M.B.A. from Boston University.

Tim Pratt is Executive Vice President, Chief Administrative Officer, General Counsel and Secretary for Boston Scientific and a member of its Executive Committee.  In this role, he is responsible for worldwide management of Boston Scientific’s Legal functions, Global Compliance, Government Affairs, Aviation, and Global Security.

Mr. Pratt served as President and Chairman of the Federation of Defense & Corporate Counsel (FDCC).  He also serves as a Director on the Boards of Lawyers for Civil Justice (LCJ), DRI - The Voice of the Defense Bar, and the New England Legal Foundation (NELF).  Mr. Pratt is a past member of the Board of Directors for the Advanced Medical Technology Association (AdvaMed) and also served on their Executive Committee.

Brad Sorenson is Senior Vice President, Manufacturing and Supply Chain for Boston Scientific and a member of its Executive Committee. In this role, he is responsible for the global manufacturing and distribution of Boston Scientific’s products.

Sorenson has more than 16 years of medical device manufacturing experience. Prior to his current role, he held a variety of Operations positions at Boston Scientific, supporting the Cardiac Rhythm Management, Neuromodulation, Interventional Cardiology, Peripheral Interventions and Structural Heart businesses. Before joining Boston Scientific, he was President and COO of QRS Diagnostic and held manufacturing management positions at Federal Cartridge.

Sorenson earned a B.A. in Economics from Gustavus Adolphus College in St. Peter, MN and an MBA from the University of Minnesota.

Eric Thépaut is Senior Vice President and President, Europe for Boston Scientific and a member of its Executive Committee. Based at the regional headquarters in Paris, he is responsible for Boston Scientific’s businesses in Europe.

Prior to his current role, Thépaut was Vice President Interventional Cardiology & Structural Heart, Europe, since 2012. He joined Boston Scientific Europe, in 1996, as a business finance manager and earned roles of increasing responsibility in Marketing and Finance, becoming Vice President, Finance, Europe, in 2002. Eric was next promoted to General Manager and Vice President, France, and then the France Group, comprised of France, Benelux and Middle East North Africa. Before coming to Boston Scientific, Eric held management positions in treasury operations and auditing at Nestlé and financial planning & analysis at Apple Computer.

Thépaut has driven innovation in high technology businesses throughout his career, leading organizational transformation initiatives and development programs as well as creating new selling models.  

Eric earned his MBA at Paris Dauphine University.

Nelda J. Connors has been a director of Boston Scientific since December 2009. Ms. Connors is the founder, Chairwoman and Chief Executive Officer of Pine Grove Holdings, LLC, a privately held investment company that acquires and operates small-to-middle market businesses primarily focused in power generation, construction equipment, advanced material and aftermarket automotive end-markets. The current Pine Grove portfolio companies are Alturdyne Power Systems, LLC, Pine Grove Properties, LLC and X-Form Power. She served as President and Chief Executive Officer of Atkore International Inc. from December 2010 until June 2011. Atkore, formerly the Electrical and Metal Products division of Tyco International, became a privately-held company in December 2010. Ms. Connors served as President of this Tyco division from 2008 through 2010. Prior to joining Tyco, she served as Vice President at Eaton Corporation from 2002 to 2008, where she held several positions in operations, continuous improvement, and general management. Prior to joining Eaton, Ms. Connors was employed in a number of executive and management capacities in the automotive industry. Her work over 25 years has involved responsibilities in the U.S., Europe, and Asia. Ms. Connors is a Class B director of the Federal Reserve Bank of Chicago, and a director of Clarcor, Inc., and Echo Global Logistics, Inc. She previously served on the boards of Atkore, Vesuvius plc and Blount International and was formerly an appointed member for the Takata Independent Quality Assurance Panel to investigate the airbag inflator recall. Ms. Connors holds B.S. and M.S. degrees in mechanical engineering from the University of Dayton.

Charles J. Dockendorff has been a director of Boston Scientific since April 2015. He was Executive Vice President and Chief Financial Officer of Covidien plc, a publicly traded medical device and supplies company, a position he held at Covidien and its predecessor, Tyco Healthcare, from 1995 to 2015. Mr. Dockendorff joined the Kendall Healthcare Products Company, the foundation of the Tyco Healthcare business, in 1989 as Controller and was named Vice President and Controller in 1994. He was appointed Chief Financial Officer of Tyco Healthcare in 1995. Prior to joining Kendall/Tyco Healthcare, Mr. Dockendorff was the Chief Financial Officer, Vice President of Finance and Treasurer of Epsco Inc. and Infrared Industries, Inc. In addition, Mr. Dockendorff worked as an accountant for Arthur Young & Company (now Ernst & Young) and the General Motors Corporation. Mr. Dockendorff is a director of Haemonetics Corporation and Keysight Technologies, Inc. Mr. Dockendorff holds a bachelor’s degree in accounting from the University of Massachusetts at Amherst and a M.S. in finance from Bentley College.

Yoshiaki Fujimori has been a director of Boston Scientific since July 2016. He is currently an adviser to the LIXIL Group Corporation, a position he has held since June 2016, and was the President and Chief Executive Officer of the LIXIL Group Corporation from August 2011 to June 2016. Prior to joining LIXIL, he was Chairman, President and Chief Executive Officer of GE Japan from January 2008 to June 2011. In his 25 years at GE, beginning in October 1986, he held a variety of positions including Senior Vice President and Chief Executive Officer of a number of Asian and global business divisions including Medical Systems, Plastics, and Capital. Mr. Fujimori also served as a member of the Corporate Executive Council from 2001 to 2010. Mr. Fujimori has been an external director of Tokyo Electric Power Company since June 2012 and an external director of Takeda Pharmaceutical Company Limited since June 2016, and formerly served as a director of the Japan Construction Material & Housing Equipment Industries Federation. Mr. Fujimori received a bachelor’s degree in petroleum engineering from the Tokyo University of Science and his M.B.A from Carnegie Mellon Graduate School of Business, where he serves as a lifetime member of the board of trustees.

Donna A. James has been a director of Boston Scientific since July 2015. She is the founder of Lardon & Associates LLC, a business development and executive advisory services firm, where she has served as president and managing director since April 2006. Ms. James has more than 30 years of diverse management and leadership experience, including her experience at Nationwide Insurance and Financial Services, where she served in a variety of roles beginning in 1981. In her 25 years at Nationwide, she served in several leadership roles, including president of Nationwide Strategic Investments, a division of Nationwide Insurance Company, from 2003 to 2006, during which time she had direct responsibility for developing and executing strategies for U.S. and global financial services subsidiaries and affiliates. Ms. James also is the founder of The Center for Healthy Families, a non-profit in Columbus, Ohio, and the former chair of the National Women’s Business Council by presidential appointment. Ms. James currently serves as a director of L Brands, Inc., and Marathon Petroleum Inc., as well as FIS Group, a privately-held asset management and investment advisory firm and formerly served as a director of Time Warner Cable Inc. from 2009 until May 2016 and Coca Cola Enterprises from 2005 until 2012. She received her B.S. in Accounting from North Carolina A&T State University.

Edward J. Ludwig has been a director of Boston Scientific since March 2014. Mr. Ludwig is the former Chairman of the board of Becton, Dickinson and Company (“BDX”), a global medical technology company, having served in that position from February 2002 through June 2012. He also served as BDX’s Chief Executive Officer from January 2000 to September 2011 and as its President from May 1999 to December 2008. Mr. Ludwig joined BDX as a senior financial analyst in 1979. Prior to joining BDX, Mr. Ludwig served as a senior auditor with Coopers and Lybrand (now PricewaterhouseCoopers) where he earned his CPA, and as a financial and strategic analyst at Kidde, Inc. Mr. Ludwig serves as lead director on Aetna Inc.’s board of directors and chairs its finance committee and is a member of the board of directors of Xylem, Inc. Additionally, Mr. Ludwig served as vice chair of the board of trustees of the Hackensack University Medical Center Network from 2012 to 2015. Mr. Ludwig received a B.A. degree in economics and accounting from The College of the Holy Cross and a M.B.A. degree from Columbia University.

Stephen P. MacMillan has been a director of Boston Scientific since April 2015. He is currently the Chairman, President and CEO of Hologic, Inc., a position he has held since June 2015, and he served as President and CEO of Hologic, Inc., since December 2013. Prior to assuming his role with Hologic, Mr. MacMillan was the Chief Executive Officer of sBioMed, LLC, a medical research company, from October 2012 to December 2013. From 2003 to 2012, Mr. MacMillan served in various roles at Stryker Corporation, including Chief Operating Officer from June 2003 to January 2005, President from June 2003 to February 2012, Chief Executive Officer from January 2005 to February 2012 and Chairman from January 2010 to February 2012. Prior to 2003, Mr. MacMillan was a senior executive with Pharmacia Corporation where he oversaw five global businesses. Prior to joining Pharmacia, Mr. MacMillan spent 11 years with Johnson & Johnson in a variety of senior roles both in the U.S. and Europe, including President of the joint venture between Johnson & Johnson and Merck. Mr. MacMillan began his career with Procter and Gamble in 1985. Additionally, Mr. MacMillan served on the board of directors of Texas Instruments Inc. from 2008 to 2012 and Alere, Inc. from 2013 to 2015. Mr. MacMillan received a Bachelor of Arts degree in Economics from Davidson College and is a graduate of Harvard Business School’s Advanced Management Program.

Michael “Mike” Mahoney is Chief Executive Officer of Boston Scientific Corporation and Chairman of the company’s board of directors. Boston Scientific is a global medical technology leader with more than $8 billion in annual revenue and commercial representation in more than 100 countries. Under Mahoney’s leadership, Boston Scientific is delivering on its mission to transform lives through innovative medical solutions that improve the health of patients around the world. The company’s team of more than 27,000 global employees reaches 24 million patients each year, providing a range of technologies and solutions that span cardiovascular and peripheral interventions, cardiac rhythm management, endoscopy, neuromodulation and urology and pelvic health. Mahoney joined Boston Scientific in October 2011 as President, and became President, Chief Executive Officer and a member of the board of directors in November 2012. He was elected Chairman in May 2016. Since joining Boston Scientific, Mahoney has focused the company on addressing the needs of the evolving healthcare landscape by driving improvements to patient outcomes and increasing healthcare economic efficiency and access. Under his leadership, Boston Scientific has brought many transformational medical devices to market while creating significant value to its shareholders. Mahoney’s career spans more than 25 years of success building market-leading medical device, capital equipment and healthcare IT businesses. Prior to Boston Scientific, he served as Worldwide Chairman of the Medical Devices and Diagnostics (MD&D) division of Johnson & Johnson, where he oversaw seven franchises and 50,000 employees. Previously, he served as Worldwide Group Chairman of Johnson & Johnson’s DePuy orthopedics and neuro-sciences business, where he drove growth through product innovation, acquisitions and market expansion into China and India. Prior to joining DePuy, Mahoney was President and Chief Executive Officer of Global Healthcare Exchange (GHX), a joint venture between Johnson & Johnson, General Electric and three other leaders in the medical device, hospital and technology industries. For the first 12 years of his career, Mahoney advanced through a series of leadership roles at General Electric Medical Systems, including General Manager of the company’s Healthcare Information Technology business. Mahoney serves on the board of directors of Baxter International and the American Heart Association leadership council. He earned a B.B.A. in Finance from the University of Iowa and his M.B.A. from Wake Forest University. He is married and has three children.

David J. Roux has been a director of Boston Scientific since January 2014. Mr. Roux is a co-founder and Senior Director of Silver Lake, a private equity firm focused on technology investing. He was formerly Chairman and Chief Executive Officer of Liberate Technologies, Executive Vice President at Oracle Corporation and Senior Vice President at Lotus Development. Mr. Roux is also Chairman of Jackson Laboratories, Chairman of Bristol Seafoods, and Vice Chairman of National Audubon Society. He previously served as a member of the boards of directors of Avaya Inc. from December 2008 until December 2012, Avaya Holdings Corp. from January 2007 until December 2012, Serena Software, Inc. from March 2006 until March 2011 and Intelsat S.A. from May 2010 until January 2012. Mr. Roux holds an M.B.A. from Harvard Business School and an M. Phil. from King’s College, Cambridge University. He is a graduate of Harvard College.

John E. Sununu has been a director since April 2009. From 2003 to 2009, Senator Sununu served as a U.S. Senator from New Hampshire. He was a member of the Committees on Banking, Commerce, Finance and Foreign Relations, and he was appointed the Congressional Representative to the United Nations General Assembly. Before his election to the Senate, Senator Sununu served three terms as a Member of the U.S. House of Representatives from New Hampshire’s 1st District from 1996 to 2002. He was Vice Chairman of the Budget Committee and a member of the Appropriations Committee. During his twelve years in Congress, he drafted and helped pass several important pieces of legislation, including the Internet Tax Freedom Act, the Survivors Benefit Act and the New England Wilderness Act. Prior to serving in Congress, Senator Sununu served as Chief Financial Officer for Teletrol Systems, a manufacturer of building control systems. Mr. Sununu formerly served as a director of Time Warner Cable Inc. until May 2016. He holds B.S. and M.S. degrees in Mechanical Engineering from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School.

Ellen M. Zane, has been a director of Boston Scientific since April 2016. Ms. Zane is Chief Executive Officer Emeritus and Vice Chair of the board of trustees at Tufts Medical Center & Floating Hospital for Children, and from 2004 to 2011, she served as its President and Chief Executive Officer. From May 1994 to January 2004, Ms. Zane served as Network President for Partners Healthcare System, a physician/hospital network sponsored by the Harvard-affiliated Massachusetts General Hospital and Brigham and Women’s Hospital. Prior to 2004, Ms. Zane served as Chief Executive Officer of Quincy Hospital in Quincy, Massachusetts. Ms. Zane is also currently a member of the board of directors at Brooks Automation, a publicly traded global provider of automation, vacuum and instrumentation solutions in the semiconductor industry, as well as life science storage technology; Parexel International Corporation, a publicly traded global bio-pharmaceutical services company; Century Capital Management, LLC, a private mutual fund company; Fiduciary Trust Company, a privately owned wealth management company; and AgNovos Healthcare, LLC, a privately held medical device company, focused on bone health. Ms. Zane previously served as a director of Lincare Holdings Inc. until it was acquired in August 2012. She also served as a director of Haemonetics Corporation until April 2016 and of Press Ganey Holdings until it was acquired in October 2016. Ms. Zane holds a Professional Director Certification from the American College of Corporate Directors. Ms. Zane earned her B.A. from George Washington University and her M.A. from Catholic University of America, both in Audiology and Speech-Language Pathology.